Title:
5'-POSITION SILYL ETHER DERIVATIVE FOR NUCLEOSIDE ANTI-CANCER AGENT OR ANTI-VIRUS AGENT
Document Type and Number:
WIPO Patent Application WO/2018/230479
Kind Code:
A1
Abstract:
[Problem] To provide a drug that replaces nucleoside anti-cancer agents or anti-virus agents clinically used as therapeutic medicines for cancer or virus infection, that is highly stable against various hydrolytic metabolic enzymes, that can be taken orally, and that is incorporated in the biosynthetic routes of DNA and RNA and produces a cytocidal effect by performing DNA or RNA modification and extension inhibition or reverse transcriptase inhibition, and protein synthesis inhibition. [Solution] A novel compound represented by formula (I) solves the above problem. (In the formula: D is the 5' position of a nucleoside anti-cancer agent or anti-virus agent; and R1, R2, and R3 are each, each optionally being the same or different, an alkyl group that may have a substituent, or an aryl alkyl group.)
More Like This:
Inventors:
SAKO MAGOICHI (JP)
SUGIYAMA SHINPEI (JP)
SUGIYAMA SHINPEI (JP)
Application Number:
PCT/JP2018/022132
Publication Date:
December 20, 2018
Filing Date:
June 11, 2018
Export Citation:
Assignee:
OHARA PHARMACEUTICAL CO LTD (JP)
International Classes:
C07H23/00; A61K31/7056; A61K31/7068; A61K31/7072; A61K31/7076; A61K47/54; A61P31/12; A61P35/00; A61P43/00; A61K31/695; C07F7/18
Domestic Patent References:
| WO2004050666A1 | 2004-06-17 | |||
| WO2004050665A1 | 2004-06-17 | |||
| WO2004052905A2 | 2004-06-24 |
Foreign References:
| US20090306008A1 | 2009-12-10 | |||
| JP2014189499A | 2014-10-06 | |||
| US20090118222A1 | 2009-05-07 | |||
| US5420117A | 1995-05-30 | |||
| US5420276A | 1995-05-30 | |||
| US20100093609A1 | 2010-04-15 | |||
| JP2006524711A | 2006-11-02 | |||
| US20030036528A1 | 2003-02-20 | |||
| US20120309705A1 | 2012-12-06 | |||
| US4908441A | 1990-03-13 | |||
| US5492897A | 1996-02-20 | |||
| US20110039798A1 | 2011-02-17 | |||
| JPH09124641A | 1997-05-13 | |||
| US20140200229A1 | 2014-07-17 | |||
| US5506349A | 1996-04-09 |
Other References:
TSYBULSKAYA, I. ET AL.: "Phospholipid derivatives of cladribine and fludarabine: Synthesis and biological properties", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 23, no. 13, 25 April 2015 (2015-04-25), pages 3287 - 3296, XP029170440
BONACHE, M. ET AL.: "Structure-activity relationship studies on a novel family of specific HIV-1 reverse transcriptase inhibitors", ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, vol. 14, no. 5, 1 October 2003 (2003-10-01), pages 249 - 262, XP055562397, Retrieved from the Internet
AGARWAL, H. K. ET AL.: "Synthesis and Anti-HIV Activities of Glutamate and Peptide Conjugates of Nucleoside Reverse Transcriptase Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 55, no. 6, 21 February 2012 (2012-02-21), pages 2672 - 2687, XP055562401, Retrieved from the Internet
BONACHE, M. ET AL.: "Structure-activity relationship studies on a novel family of specific HIV-1 reverse transcriptase inhibitors", ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, vol. 14, no. 5, 1 October 2003 (2003-10-01), pages 249 - 262, XP055562397, Retrieved from the Internet
AGARWAL, H. K. ET AL.: "Synthesis and Anti-HIV Activities of Glutamate and Peptide Conjugates of Nucleoside Reverse Transcriptase Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 55, no. 6, 21 February 2012 (2012-02-21), pages 2672 - 2687, XP055562401, Retrieved from the Internet
Attorney, Agent or Firm:
SHA Takuho (JP)
Download PDF:
Previous Patent: FLOW MEASURING DEVICE
Next Patent: LINE DISTINGUISHING DEVICE AND LINE DISTINGUISHING METHOD
Next Patent: LINE DISTINGUISHING DEVICE AND LINE DISTINGUISHING METHOD